Author

W. Christ

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 3 Organism:human· 3 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Assay:flow cytometry· 1

Frequent Co-Authors

G. Ahlen· 2 shared H.-G. Ljunggren· 2 shared J. Klingstrom· 2 shared J. Klingström· 2 shared J. T. Sandberg· 2 shared J. Tynell· 2 shared K. Blom· 2 shared K. T. Maleki· 2 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

G. Ahlen

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Discovery of a novel inhibitor of macropinocytosis with antiviral activity

B. Porebski, W. Christ, A. Corman, M. Haraldsson, M. Barz, L. Lidemalm, M. Haggblad, J. Illmain, S. Wright, M. Murga, J. Schlegel, E. Sezgin, G. Bhabha, V. M. Lauschke, M. Lafarga, , O. Fernandez-Capetillo

This study identifies virapinib, a novel inhibitor of macropinocytosis that blocks viral entry by SARS-CoV-2, Monkeypox virus, and TBEV without host cell toxicity.

bioRxiv · Oct 25, 2023Pharmacology & Toxicology

SARS-CoV-2 variant-specific differences in inhibiting the effects of the PKR-activated integrated stress response

W. Christ, J. Klingstrom, J. Tynell

This study examines how different SARS-CoV-2 variants affect the integrated stress response by varying their activation of PKR and downstream effects.

bioRxiv · Dec 21, 2022Microbiology

Longitudinal characterization of humoral and cellular immunity in hospitalized COVID-19 patients reveal immune persistence up to 9 months after infection

J. T. Sandberg, R. Varnaite, W. Christ, P. Chen, J. R. Muvva, K. T. Maleki, M. Garcia, M. Dzidic, E. Folkesson, M. Skagerberg, G. Ahlen, L. Frelin, M. Sällberg, The Karolinska COVID-19 Study Group, L. I. Eriksson, , S. Gredmark-Russ

This study tracks immune responses in hospitalized COVID-19 patients up to 9 months post-infection, showing persistent neutralizing antibodies and memory B and T cells.

bioRxiv · Mar 17, 2021 · PreprintImmunology

Expansion of SARS-CoV-2-specific Antibody-secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients

R. Varnaite, M. Garcia, H. Glans, K. T. Maleki, J. T. Sandberg, J. Tynell, W. Christ, N. Lagerqvist, H. Asgeirsson, H.-G. Ljunggren, G. Ahlen, L. Frelin, M. Sällberg, K. Blom, J. Klingström, S. Gredmark-Russ

This study examines B cell and antibody responses in hospitalized COVID-19 patients, finding expanded SARS-CoV-2-specific antibody-secreting cells and neutralizing antibodies.

bioRxiv · May 28, 2020Immunology